CELEX: 62015TN0041
Language: en
Date: 2015-01-23 00:00:00
Title: Case T-41/15: Action brought on 23 January 2015 — Novartis v OHIM — Mabxience (HERTIXAN)

30.3.2015   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 107/32
            
         
      Action brought on 23 January 2015 — Novartis v OHIM — Mabxience (HERTIXAN)
      (Case T-41/15)
      (2015/C 107/42)
      Language in which the application was lodged: English
      
         Parties
      
      
         Applicant: Novartis AG (Basel, Switzerland) (represented by: M. Douglas, lawyer)
      
         Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)
      
         Other party to the proceedings before the Board of Appeal: Mabxience SA (Montevideo, Uruguay)
      
         Details of the proceedings before OHIM
      
      
         Applicant: Other party to the proceedings before the Board of Appeal
      
         Trade mark at issue: Community word mark ‘HERTIXAN’ — Application for registration No 10 660 835
      
         Procedure before OHIM: Opposition proceedings
      
         Contested decision: Decision of the First Board of Appeal of OHIM of 31 October 2014 in Case R 2550/2013-1
      
         Form of order sought
      
      The applicant claims that the Court should:
      
                  —
               
               
                  annul the contested decision;
               
            
                  —
               
               
                  order OHIM to pay the costs.
               
            
         Plea(s) in law
      
      
                  —
               
               
                  Infringement of Article 8(1)(b) of Regulation No 207/2009;
               
            
                  —
               
               
                  Infringement of Article 42(2) and (3) of Regulation No 207/2009;
               
            
                  —
               
               
                  Infringement of Article 75 of Regulation No 207/2009.